Penumbra (PEN)

• Market cap: $9.13B
• 1 day: 1.85%
• 5 days: -0.05%
• 1 month: 15.11%
• 3 months: 25.67%
• 6 months: 16.19%
• Year to date: -2.83%
• 1 year: 4.37%
• 5 years: 42.62%
• 10 years: 475.88%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Employees: 4,200

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

17% more call options, than puts

Call options by funds: $68.2M | Put options by funds: $58.5M

5% more capital invested

Capital invested by funds: $6.45B [Q2] → $6.78B (+$323M) [Q3]

2.94% less ownership

Funds ownership: 92.66% [Q2] → 89.72% (-2.94%) [Q3]

5% less funds holding

Funds holding: 339 [Q2] → 322 (-17) [Q3]

26% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 66

28% less repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 137

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $200 16% downside
• Avg. target: $233 2% downside
• High target: $263 11% upside

11 analyst ratings

• positive: 10 91%
• neutral: 1 9%
• negative: 0 0%

Piper Sandler Matt O'Brien 60% 1-year accuracy 30 / 50 met price target	1% downside $235	Overweight Maintained	31 Oct 2024
Baird David Rescott 81% 1-year accuracy 13 / 16 met price target	4% upside $248	Outperform Maintained	31 Oct 2024
Piper Sandler Matt O'Brien 60% 1-year accuracy 30 / 50 met price target	5% downside $225	Overweight Reiterated	18 Oct 2024
Canaccord Genuity Jason Mills 67% 1-year accuracy 4 / 6 met price target	1% downside $235	Buy Maintained	16 Oct 2024
BTIG Ryan Zimmerman 66% 1-year accuracy 29 / 44 met price target	2% downside $234	Buy Maintained	14 Oct 2024